Articles

The Biotechnology Entrepreneurship Boot Camp at the 2011 BIO International convention is an intensive three day course designed for entrepreneurial scientists, CEOs, CSOs and business development professionals of early stage companies in the life sciences who are aspiring entrepreneurs.

The Biotechnology Entrepreneurship Boot Camp at the 2011 BIO International convention is an intensive three day course designed for entrepreneurial scientists, CEOs, CSOs and business development professionals of early stage companies in the life sciences who are aspiring entrepreneurs.

To carry out military and humanitarian missions around the world, U.S. forces require reliable fuel supplies and secure supply lines. At the micro level, the military is as much at the mercy of high oil and gasoline prices as the average consumer. In addition, when you calculate the fully burdened cost of fuels, for instance a gallon of jet fuel delivered to the front lines in Afghanistan, it can be upwards of $400 per gallon. And, on a macro level, oil often comes from regions of the world that are not U.S. military allies. The need for great energy independence is therefore a very important national security issue.

The Therapeutic Discovery Project (TDP) was enacted in 2010 to provide bridge financing to small biotechnology companies conducting groundbreaking research. The program awarded $1 billion in credits and grants to nearly 3,000 biotech companies, creating jobs, bolstering U.S. competitiveness, and advancing the search for cures and breakthrough medicines. BIO supports extending and expanding this important program.

What is the Intellectual Property Counsels Committee (IPCC)?

Biotech-related agricultural trade problems include bilateral trade problems with the European Union (EU), China and Korea, and involve multilateral discussions in the Codex and the World Trade Organization (WTO).

The International Leader Award honors individuals who have shown a strong commitment to advancing biotechnology through policy mechanisms that facilitate and strengthen a country or region's foundation for innovation.

BIO International Convention

Global energy demand is projected to grow 50 percent by 2025 while we also face a dwindling supply of fossil fuels and the looming threat of climate change.

Infectious diseases are the second leading cause of death worldwide, and new infectious diseases continue to emerge. Infants and children are among the most susceptible.

Perhaps the biggest challenge facing the world today is how to feed seven billion people and ensure that no child ever goes to bed hungry.

At its simplest, biotechnology is technology based on biology - biotechnology harnesses cellular and biomolecular processes to develop technologies and products that help improve our lives and the health of our planet.

According to the American College of Sports Medicine, Washington, DC tops the ranks of the fittest cities in the nation. With the 2011 BIO International Convention quickly approaching, BIO hopes visitors will get active.  From the BIO 5K Run/Walk to the BIO Golf Outing (both hosted by Novo Nordisk Inc) to the various outdoor activities right at our fingertips in the nation’s capital, attendees are encouraged to get outside and take advantage of all the city has to offer.

Deb Bowes from Women in Bio discusses plans for the upcoming BIO International Convention, the critical role of women’s leadership in biotechnology, and why she is personally committed to Women in Bio and its mission.

BIOtechNOW’s Tracy Cooley talks to Dr. Almond of Sanofi Pasteur about the International BioGENEius Challenge, which will be presented at the upcoming BIO International Convention.

A report on the benefits for health care, nutrition, the environment, and animal welfare.

BIOtechNOW’s Tracy Cooley talks to Dr. Reed from the Sanford-Burnham Medical Institute about the NIH’s new National Center for Advancing Translational Sciences.

“I’ve never been a farmer,” Bill Gates confessed at The Chicago Council’s Symposium on Global Agriculture and Food Security. “Until recently, I rarely set foot on a farm.”

WASHINGTON, D.C. (Tuesday, April 19, 2011) - The Biotechnology Industry Organization (BIO) announced today that Dr. Jörg Reinhardt, CEO of Bayer HealthCare, will provide the keynote address at the BIO China International Conference to be held October 12-13 in Shanghai, China. The event will bring together biotechnology and pharmaceutical leaders to explore business opportunities with life science companies in China.

All programs at the BIO World Congress on Industrial Biotechnology and Bioprocessing are open to attendance by members of the media. Complimentary media registration is available to editors and reporters with valid press credentials working full time for print, broadcast or web publications.

Despite the fact that U.S. Secretary of Agriculture Tom Vilsack believes that the regulation of genetically engineered agricultural products must be science-based, and that he has “no doubts about the safety of the products this system has approved and will continue to approve,” some state legislatures are considering bills requiring labeling for biotech-derived food. These bills defy existing science-based regulation and are wholly unnecessary.

Some of the most pressing challenges for the advent of personalized medicine relate to the reimbursement of novel diagnostics. Reimbursement policies must reflect the potential benefit that novel diagnostics can bring to patients and the healthcare system. This value proposition can be realized through reimbursement policy reforms that provide a clear and consistent pathway to obtain affirmative coverage, appropriate and timely coding, and market-based payment for diagnostic tests. BIO recommends that the following reforms be made to diagnostic reimbursement policy.

Klein is chairman of the governing board and a member of the peer review committee for the  California Institute for Regenerative Medicine. The Biotechnology Humanitarian Award is given out each year at the BIO International Convention .

Dr. Jay Siegel of  Johnson & Johnson Pharmaceutical Research & Development  and Janelle Curtis from the  Biotechnology Institute  discuss this year’s International BioGENEius Challenge.